Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis

被引:22
|
作者
Liu, Mingsu [1 ,2 ]
Zheng, Yang [1 ,2 ]
Li, Guangqin [1 ,2 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China
[2] Chongqing Key Lab Neurobiol, Chongqing, Peoples R China
来源
关键词
Stroke; anticoagulation; recanalization therapy; safety; TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; ANTAGONIST ORAL ANTICOAGULANTS; INTRAVENOUS THROMBOLYSIS; ENDOVASCULAR THROMBECTOMY; ATRIAL-FIBRILLATION; HEMORRHAGIC TRANSFORMATION; INTRACEREBRAL HEMORRHAGE; DABIGATRAN ETEXILATE; EARLY MANAGEMENT;
D O I
10.1016/j.jstrokecerebrovasdis.2018.04.012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Intravenous thrombolysis treatment (IVT) and endovascular therapy (EVT) have been proved as fist-line beneficial option for eligible patients who have acute ischemic stroke (AIS) with major safety concern of symptomatic intracranial hemorrhage (sICH). Unfortunately, the emergency management of patients with AIS taking vitamin K antagonists and with international normalized ratio higher than 1.7 or taking new oral anticoagulants (NOACs) represents a great challenge. We aim to comprehensively determine the safety of EVT in patients under prior-stroke anticoagulants and IVT in patients under NOAC use. Methods: Clinical researches published in the Embase, PubMed, and Cochrane Library electronic databases up to December 2017 were identified for analysis. Subgroup and sensitivity analyses were also conducted to evaluate the robustness of the conclusions. Results: Overall, 9 studies involving 3885 patients met the inclusion criteria. The rate of sICH (risk ratio [RR] = .94, 95% CI = .61-1.47, P = .799), mortality (P = .495), and recanalization (P = .655) after EVT did not differ between patients under and those who were not under anticoagulants, although patients under anticoagulants were less likely to achieve good functional outcome (P < .001) than those who were not. Moreover, prior NOAC therapy was not significantly associated with increasing sICH in patients with AIS after IVT (RR = .79, 95% CI = .41-1.53, P = .492). Conclusions: Patients under anticoagulation appear to be safe after EVT with relatively lower rate of good outcome; furthermore, prior NOAC therapy was not associated with an increasing sICH rate after IVT. This offered a practical information to select appropriate therapeutic strategies for patients under anticoagulation, although the level of evidence seems to be quite shaky.
引用
收藏
页码:2296 / 2305
页数:10
相关论文
共 50 条
  • [21] Efficacy and safety of Shenmai injection for acute ischemic stroke: a systematic review and meta-analysis
    Zhao, Shuai
    Sun, Tianye
    Zhang, Mi
    Yan, Mingyuan
    Wang, Kaiyue
    Li, Lili
    Liu, Jinmin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Safety and Efficacy of Early Antiplatelet Therapy in Acute Ischemic Stroke Patients Receiving Endovascular Treatment: A Systematic Review and Meta-analysis
    Tang, Qin
    CEREBROVASCULAR DISEASES, 2019, 48 : 102 - 102
  • [23] Safety and efficacy of early antiplatelet therapy in acute ischemic stroke patients receiving endovascular treatment: A systematic review and meta-analysis
    Guo, Yijia
    Lin, Yapeng
    Tang, Yifang
    Tang, Qin
    Wang, Xiaoqing
    Pan, Xiding
    Zou, JianJun
    Yang, Jie
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 66 : 45 - 50
  • [24] Safety and Efficacy of Intravenous Thrombolysis and Endovascular Therapy in Children with Acute Ischemic Stroke: A Systematic Review and Meta-analysis
    Pacheco, Juliana
    Winzer, Simon
    Barlinn, Jessica
    Reichmann, Heinz
    Puetz, Volker
    Siepmann, Timo
    Barlinn, Kristian
    STROKE, 2017, 48
  • [25] Impact of prior antiplatelet therapy on safety and efficacy of alteplase in acute ischemic stroke: a systematic review and meta-analysis
    Naeem, Ahmed
    Kelani, Hesham
    Salamah, Hazem Mohamed
    Elhalag, Rowan H.
    Ali, Hossam Tharwat
    Hussein, Ayham Mohammad
    Abdelnasser, Omar
    Naguib, Mostafa Mahmoud
    Elshenawy, Salem
    Abdelwahab, Abdelrhman M.
    Albaramony, Nadia
    Rageh, Omar El Sayed
    Allam, Abdallah R.
    Bakr, Aliaa
    Abuelazm, Mohamed
    Madkoor, Ahmed
    Quinoa, Travis R.
    Kay, Arthur D.
    Lerner, David P.
    Merlin, Lisa R.
    Raz, Eytan
    Spiotta, Alejandro M.
    Mayer, Stephan A.
    NEUROLOGICAL SCIENCES, 2025,
  • [26] Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis
    Zhao, Kun
    Li, Guang-zong
    Nie, Liu-yan
    Ye, Xiang-ming
    Zhu, Gen-ying
    CLINICAL THERAPEUTICS, 2022, 44 (12) : e29 - e38
  • [27] Ancrod for acute ischemic stroke: A systematic review and meta-analysis
    Demaerschalk, Bart M.
    Bobrow, Bentley
    STROKE, 2007, 38 (02) : 506 - 506
  • [28] Tirofiban for acute ischemic stroke: systematic review and meta-analysis
    Gong, Jinhong
    Shang, Jingjing
    Yu, Hai
    Wan, Qian
    Su, Dan
    Sun, Zhiqiang
    Liu, Guangjun
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (04) : 475 - 481
  • [29] NEUROMODULATION IN ACUTE ISCHEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Pellegrino, M.
    Salles, I.
    Shinosaki, J.
    Reis, S.
    Nogueira, R.
    Conforto, A.
    INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (2_SUPPL) : 71 - 71
  • [30] Tirofiban for acute ischemic stroke: systematic review and meta-analysis
    Jinhong Gong
    Jingjing Shang
    Hai Yu
    Qian Wan
    Dan Su
    Zhiqiang Sun
    Guangjun Liu
    European Journal of Clinical Pharmacology, 2020, 76 : 475 - 481